Global Chronic Lower Back Pain Drugs Market - 2023-2030

Global Chronic Lower Back Pain Drugs Market - 2023-2030

Global chronic lower back pain drugs market reached US$ XX billion in 2022 and is expected to reach US$ XX billion by 2030, growing with a CAGR of XX% during the forecast period 2023-2030.

Chronic lower back pain drugs are medications used to manage persistent and long-term lower back pain. This type of pain typically lasts for more than 12 weeks and can result from various underlying causes, including musculoskeletal issues, degenerative conditions, injuries, or structural abnormalities in the spine. The drugs aim to alleviate pain, reduce inflammation, and improve the quality of life for individuals living with this condition.

Chronic lower back pain drugs encompass a range of medication classes, including nonsteroidal anti-inflammatory drugs, analgesics, antidepressants, opioids, among others. Furthermore, the increasing prevalence of chronic lower back pain, and increasing clinical trials of drugs are the factors expected to drive the market over the forecast period.

Market Dynamics

Increasing Clinical Trials of Drugs is Expected to Drive Market Growth

According to ClinicalTrials.Gov, the trial conducted by Vertanical GmbH, of VER-01 in the treatment of patients with chronic non-specific low back pain, commenced on July 7, 2021, and is estimated to reach primary completion by October 16, 2023, with an overall study completion date projected for May 27, 2024.

This timeline outlines a clinical trial for VER-01, a potential medication designed to address chronic non-specific low back pain. If VER-01 is found to be effective in relieving chronic low back pain and also has a favorable safety profile, it could become a valuable addition to the range of treatment options available for this condition. This could lead to an increase in demand for this medication by healthcare providers and patients.

Increasing Prevalence of Osteoarthritis is Expected to Drive the Market Growth

According to a study published in the journal Arthritis & Rheumatology, the prevalence of Osteoarthritis (OA) is a major public health concern worldwide. The study reveals that age-standardized OA rates are continuously increasing, as per the Global Burden of Disease Study 2019 data.

Over nearly three decades, the number of cases of osteoarthritis (OA) has increased by more than double. From 247.51 million cases in 1990 to 527.81 million cases in 2019, the trend is particularly noticeable in the knee and hip joints. This highlights the significant burden that OA poses, especially in larger joints where it can result in severe disability and even require joint replacements.

As a result, healthcare providers may prioritize implementing more comprehensive pain management strategies to address the increasing prevalence of OA. This could also potentially benefit the chronic lower back pain drugs market as the demand for effective pain relief options rises not only for OA but also for conditions such as chronic lower back pain that are associated with musculoskeletal issues.

Safety Concerns of Drugs are Expected to Hamper the Market Growth

The market for drugs that treat chronic lower back pain has been greatly impacted by the opioid crisis. Opioids like oxycodone and hydrocodone were previously prescribed as they were effective in relieving pain. However, due to the risks of addiction, overdose, and other side effects, these drugs are now subject to stricter regulations and increased scrutiny.

Segment Analysis

The global chronic lower back pain drugs market is segmented based on drug class, route of administration, distribution channel and region.

The Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) from the Drug Class Segment Accounted for Approximately 37.6% of the Chronic Lower Back Pain Drugs Market Share

Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) are a type of medication that is commonly used to manage pain and inflammation. They are often the first choice for treating chronic lower back pain.

NSAIDs are effective in reducing pain by targeting the body's inflammatory response. Inflammation frequently accompanies chronic lower back pain, and it can contribute to the discomfort and severity of the pain. NSAIDs work by inhibiting enzymes called cyclooxygenases (COX), specifically COX-1 and COX-2. These enzymes play a crucial role in the production of prostaglandins, which are chemical messengers that promote pain, fever, and inflammation. By blocking COX enzymes, NSAIDs reduce the production of prostaglandins, leading to pain relief.

NSAIDs are not only helpful in relieving pain but can also decrease inflammation in the affected area. Chronic lower back pain can be caused by a variety of factors such as muscle strain, injury, or degenerative conditions like osteoarthritis, all of which can lead to inflammation. NSAIDs can help to alleviate the inflammatory response, thereby reducing pain and improving mobility.

For instance, Ibuprofen (Advil, Motrin), Naproxen (Aleve), and Celecoxib (Celebrex) among others are the OTC drugs used for chronic lower back pain. Furthermore, owing to the proven effectiveness in managing pain and inflammation, easy accessibility, affordability, patient preference, and its role as a standard treatment option in addressing the chronic nature of the condition are the factors expected to drive the market over the forecast period.

Geographical Penetration

North America Accounted for Approximately 40.3% of the Market Share in 2022, Owing to the Increasing Prevalence of Chronic Lower Back Pain, and Increasing Clinical Trials

North America region is expected to hold the largest market share over the forecast period owing to the increasing prevalence of chronic lower back pain and increasing clinical trials. For instance, according to the Cleveland Clinic, low back pain is a common problem that affects 4 out of 5 individuals at some point in their lives. This susceptibility is mainly due to the continuous degeneration of the cushion-like discs between the vertebrae in the spine, which becomes more prevalent after the age of 30.

In addition to this, some factors can increase the risk of developing low back pain, such as being overweight. Excess weight puts added pressure on the joints and spinal discs, which can lead to pain. Furthermore, due to medical conditions such as herniated discs and spinal stenosis, lifestyle factors like smoking, excessive drinking, and a sedentary lifestyle can also increase the risk of low back pain.

Also, people who suffer from depression and anxiety are more likely to develop this condition. Further, the North American Spine Society states that individuals who have experienced acute low back pain in the past are at a higher risk of developing chronic symptoms. Therefore, there is an increase in the demand and adoption of chronic lower back pain drugs.

Competitive Landscape

The major global players in the chronic lower back pain drugs market include Johnson & Johnson Consumer Inc., GSK plc, Bayer, Pfizer Inc., Viatris Inc., Eli Lilly and Company, Sanofi, Novartis AG, Dr. Reddy’s Laboratories Ltd., and Sun Pharmaceutical Industries Ltd among others.

COVID-19 Impact Analysis

The COVID-19 pandemic has brought about significant changes in people's daily routines due to lockdowns and social distancing measures. As a result, some individuals may have become more sedentary, worsening their chronic lower back pain.

With healthcare systems being overwhelmed by the demands of treating COVID-19 patients, non-urgent medical procedures and appointments, including those related to chronic pain management, were postponed or canceled. This delay in care has affected some patients' access to prescribed medications.

The pandemic has caused an acceleration in the adoption of telehealth and remote medical consultations. Although this has provided continuity of care for some chronic pain patients, it may not have been as effective as in-person visits in managing medications, dose adjustments, and monitoring potential side effects.

Furthermore, the psychological impact of the pandemic, such as anxiety, depression, and stress, can worsen chronic pain conditions. This may have prompted some patients to seek additional or alternative treatments for their chronic lower back pain. Despite the challenges that arise from the pandemic, there may also be opportunities for innovation and improved pain management strategies in the future.

Why Purchase the Report?
• To visualize the global chronic lower back pain drugs market segmentation based on drug class, route of administration, distribution channel and region as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of chronic lower back pain drugs market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as excel consisting of key products of all the major players.

The global chronic lower back pain drugs market report would provide approximately 61 tables, 60 figures, and 186 Pages.

Target Audience 2023
• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies